MX2010009736A - Compuesto heterociclico. - Google Patents
Compuesto heterociclico.Info
- Publication number
- MX2010009736A MX2010009736A MX2010009736A MX2010009736A MX2010009736A MX 2010009736 A MX2010009736 A MX 2010009736A MX 2010009736 A MX2010009736 A MX 2010009736A MX 2010009736 A MX2010009736 A MX 2010009736A MX 2010009736 A MX2010009736 A MX 2010009736A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compound
- disclosed
- formulae
- diabetes
- prevention
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Se describe un agente para la prevención y tratamiento de diabetes, el cual tiene excelentes efectos medicinales. Específicamente se describe un compuesto representado por la fórmula (I) o (lA) o una de sus sales. (En las fórmulas, los símbolos se definen como en la descripción.). (ver fórmulas).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008055250 | 2008-03-05 | ||
JP2009025511 | 2009-02-06 | ||
PCT/JP2009/054095 WO2009110520A1 (ja) | 2008-03-05 | 2009-03-04 | 複素環化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009736A true MX2010009736A (es) | 2010-09-30 |
Family
ID=41056073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009736A MX2010009736A (es) | 2008-03-05 | 2009-03-04 | Compuesto heterociclico. |
Country Status (21)
Country | Link |
---|---|
US (1) | US8436043B2 (es) |
EP (1) | EP2251326A4 (es) |
JP (1) | JP5465658B2 (es) |
KR (1) | KR101616140B1 (es) |
CN (1) | CN102015641B (es) |
AU (1) | AU2009220615B2 (es) |
BR (1) | BRPI0912245A2 (es) |
CA (1) | CA2717138A1 (es) |
CO (1) | CO6321238A2 (es) |
CR (1) | CR11688A (es) |
DO (1) | DOP2010000267A (es) |
EA (1) | EA019752B1 (es) |
EC (1) | ECSP10010526A (es) |
GE (1) | GEP20135844B (es) |
IL (1) | IL207757A (es) |
MA (1) | MA32171B1 (es) |
MX (1) | MX2010009736A (es) |
MY (1) | MY158982A (es) |
NZ (1) | NZ588011A (es) |
WO (1) | WO2009110520A1 (es) |
ZA (1) | ZA201006511B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EA015687B1 (ru) | 2006-05-04 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Полиморфы |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010050445A1 (ja) * | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
JP5746631B2 (ja) | 2009-03-10 | 2015-07-08 | 武田薬品工業株式会社 | ベンゾフラン誘導体 |
WO2011027849A1 (ja) * | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | 複素環化合物 |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
JP5711151B2 (ja) * | 2010-01-06 | 2015-04-30 | 武田薬品工業株式会社 | インドール誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
PT2566469T (pt) | 2010-05-05 | 2023-01-10 | Boehringer Ingelheim Int | Terapia de combinação |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP2585101A1 (en) | 2010-06-24 | 2013-05-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
KR101585840B1 (ko) | 2011-02-08 | 2016-01-15 | 화이자 인코포레이티드 | 글루카곤 수용체 조절자 |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CA2868713A1 (en) | 2012-03-29 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
KR102021114B1 (ko) | 2017-01-24 | 2019-09-11 | 주식회사 엘지화학 | 페놀의 정제 방법 |
US11384060B2 (en) * | 2017-01-24 | 2022-07-12 | Alphala Co., Ltd. | Amide compounds and use thereof |
EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
WO2023250316A1 (en) * | 2022-06-22 | 2023-12-28 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4793717A (en) | 1982-05-06 | 1988-12-27 | Minnesota Mining And Manufacturing Company | Device for visually indicating a pressure or temperature condition |
US7015218B1 (en) | 1999-02-10 | 2006-03-21 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
DK1285651T3 (da) | 2000-04-28 | 2010-12-13 | Takeda Pharmaceutical | Melanin-koncentrerende hormon-antagonister |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
WO2003048109A1 (en) * | 2001-12-03 | 2003-06-12 | Novo Nordisk A/S | Novel glucagon antagonists |
US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
WO2004002480A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
AR042086A1 (es) | 2002-11-21 | 2005-06-08 | Upjohn Co | N-aril-2- oxazolidinon -5- carboxamidas y sus derivados, usados como agentes antibacterianos |
DE602004030318D1 (de) | 2003-01-27 | 2011-01-13 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
US7396935B2 (en) * | 2003-05-01 | 2008-07-08 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
WO2004100875A2 (en) * | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
DK1756064T3 (da) | 2004-06-04 | 2008-09-22 | Merck & Co Inc | Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
AU2005272043B2 (en) * | 2004-07-07 | 2010-07-29 | Merck Sharp & Dohme Corp. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
ATE468853T1 (de) * | 2004-07-22 | 2010-06-15 | Merck Sharp & Dohme | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
JP2006112549A (ja) | 2004-10-15 | 2006-04-27 | Jtekt Corp | 自在継手 |
CA2600159A1 (en) | 2005-03-21 | 2006-09-28 | Merck & Co., Inc. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
MX2007016203A (es) | 2005-06-29 | 2008-03-10 | Compumedics Ltd | Ensamble de sensor con puente conductivo. |
JP5577006B2 (ja) | 2005-07-01 | 2014-08-20 | 味の素株式会社 | 迅速スクリーニング方法及び該方法で得られた微生物 |
US7799820B2 (en) | 2005-09-30 | 2010-09-21 | Banyu Pharmaceutical Co., Ltd. | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions |
SI1951661T1 (sl) * | 2005-11-17 | 2012-11-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava interapevtske uporabe |
WO2007089031A1 (en) | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
-
2009
- 2009-03-04 EP EP09717906A patent/EP2251326A4/en not_active Withdrawn
- 2009-03-04 EA EA201071032A patent/EA019752B1/ru not_active IP Right Cessation
- 2009-03-04 WO PCT/JP2009/054095 patent/WO2009110520A1/ja active Application Filing
- 2009-03-04 CN CN200980116371.3A patent/CN102015641B/zh not_active Expired - Fee Related
- 2009-03-04 KR KR1020107022118A patent/KR101616140B1/ko not_active IP Right Cessation
- 2009-03-04 US US12/920,973 patent/US8436043B2/en not_active Expired - Fee Related
- 2009-03-04 NZ NZ588011A patent/NZ588011A/en not_active IP Right Cessation
- 2009-03-04 GE GEAP2009011962 patent/GEP20135844B/en unknown
- 2009-03-04 AU AU2009220615A patent/AU2009220615B2/en not_active Ceased
- 2009-03-04 JP JP2010501939A patent/JP5465658B2/ja not_active Expired - Fee Related
- 2009-03-04 BR BRPI0912245A patent/BRPI0912245A2/pt not_active IP Right Cessation
- 2009-03-04 CA CA2717138A patent/CA2717138A1/en not_active Abandoned
- 2009-03-04 MX MX2010009736A patent/MX2010009736A/es active IP Right Grant
- 2009-03-04 MY MYPI2010004008A patent/MY158982A/en unknown
-
2010
- 2010-08-23 IL IL207757A patent/IL207757A/en not_active IP Right Cessation
- 2010-09-03 DO DO2010000267A patent/DOP2010000267A/es unknown
- 2010-09-10 ZA ZA2010/06511A patent/ZA201006511B/en unknown
- 2010-09-23 CR CR11688A patent/CR11688A/es unknown
- 2010-09-29 MA MA33207A patent/MA32171B1/fr unknown
- 2010-10-04 CO CO10122832A patent/CO6321238A2/es active IP Right Grant
- 2010-10-05 EC EC2010010526A patent/ECSP10010526A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP10010526A (es) | 2010-11-30 |
CR11688A (es) | 2010-12-08 |
US20120270865A2 (en) | 2012-10-25 |
US8436043B2 (en) | 2013-05-07 |
AU2009220615A1 (en) | 2009-09-11 |
IL207757A (en) | 2015-07-30 |
NZ588011A (en) | 2012-06-29 |
CN102015641B (zh) | 2014-01-01 |
KR101616140B1 (ko) | 2016-04-27 |
GEP20135844B (en) | 2013-06-10 |
JPWO2009110520A1 (ja) | 2011-07-14 |
DOP2010000267A (es) | 2010-09-30 |
EP2251326A1 (en) | 2010-11-17 |
BRPI0912245A2 (pt) | 2019-09-24 |
WO2009110520A1 (ja) | 2009-09-11 |
MA32171B1 (fr) | 2011-03-01 |
IL207757A0 (en) | 2010-12-30 |
CA2717138A1 (en) | 2009-09-11 |
AU2009220615A2 (en) | 2010-11-11 |
EA019752B1 (ru) | 2014-06-30 |
CN102015641A (zh) | 2011-04-13 |
EA201071032A1 (ru) | 2011-06-30 |
CO6321238A2 (es) | 2011-09-20 |
AU2009220615B2 (en) | 2013-12-19 |
ZA201006511B (en) | 2011-11-30 |
KR20100126470A (ko) | 2010-12-01 |
EP2251326A4 (en) | 2011-08-31 |
US20120053173A1 (en) | 2012-03-01 |
JP5465658B2 (ja) | 2014-04-09 |
MY158982A (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009736A (es) | Compuesto heterociclico. | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
SG178952A1 (en) | Chemical compounds | |
TN2012000401A1 (en) | Heterocyclic compound | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
UA106748C2 (uk) | Похідні проліну як інгібітори катепсину | |
TN2009000129A1 (en) | Indole compound | |
IN2012DN01233A (es) | ||
TN2012000248A1 (en) | Novel spiropiperidine compounds | |
HK1158192A1 (en) | Piperidine gpcr agonists | |
MY149648A (en) | Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
MY153915A (en) | Organic compounds | |
WO2009051244A1 (ja) | 複素環化合物 | |
WO2008136428A1 (ja) | 含窒素5員複素環化合物 | |
MX2010002419A (es) | (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento. | |
MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
GB0812642D0 (en) | Compounds | |
UA104422C2 (uk) | Похідні індолу та їх застосування для профілактики або лікування діабету або ожиріння | |
MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
NZ597483A (en) | N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives | |
WO2012044567A3 (en) | Imidazole derivatives | |
EP2602254A4 (en) | HETEROCYCLIC COMPOUND | |
DE602008002598D1 (en) | Cyclohexylderivate | |
MX2012004087A (es) | Sulfonamidas para la prevencion de diabetes. | |
MX2013014161A (es) | Derivados de imidazol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |